Markets Stifel cuts Acorda Therapeutics PT to $1 from $2.50 Stifel reduced its price target for Acorda Therapeutics (NASDAQ:ACOR) to $1 from $2.50 and maintained its “hold” rating, citing lower than expected first quarter revenue for its Inbrija inhaled formulation of levodopa... May 6, 2020